Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game. Roblin X, Paul S, Nancey S. Aliment Pharmacol Ther 2021;53:640-641.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Roblin X, Paul S, Nancey S. Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game. Aliment Pharmacol Ther 2021;53:640-641.
PMID: 33566421